Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiasma Inc.

www.chiasmapharma.com

Latest From Chiasma Inc.

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies

Persistence Pays Off For Chiasma And Its Oral Acromegaly Therapy

Chiasma has bounced back from a 2016 CRL for Mycapssa with a new SPA-agreed Phase III trial meeting all its primary and secondary endpoints. The product is positioned to be the first oral treatment for acromegaly.

Clinical Trials Companies

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Pre-approval Promotion: Corporate Communications May Draw US FDA Scrutiny

Biopharma sponsors should start with information that needs to be disclosed to satisfy SEC rules and understand how a press release will be used to avoid running afoul of agency regulations, industry exec says; company contracts with investigators also should set limits on what they can say about an unapproved drug.

Advertising, Marketing & Sales Compliance
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Chiasma (Israel) Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Chiasma Inc.
  • Senior Management
  • Raj Kannan, CEO
    Asi Haviv, VP, Clin. Dev.
    Dana Gelbaum, VP, Global Mktg. & Corp. Dev.
    Mark J Fitzpatrick, Pres.
    Drew Enamait, VP, Fin. & Admin.
  • Contact Info
  • Chiasma Inc.
    Phone: (972)(844) 304-2462
    460 Totten Pond Rd., Ste. 530
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register